CN116407576A - Pharmaceutical composition and application of preparation thereof in preparation of medicines for treating cancers - Google Patents
Pharmaceutical composition and application of preparation thereof in preparation of medicines for treating cancers Download PDFInfo
- Publication number
- CN116407576A CN116407576A CN202111626099.2A CN202111626099A CN116407576A CN 116407576 A CN116407576 A CN 116407576A CN 202111626099 A CN202111626099 A CN 202111626099A CN 116407576 A CN116407576 A CN 116407576A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- cancer
- cells
- rat
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 65
- 229940079593 drug Drugs 0.000 title claims abstract description 49
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 47
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 38
- 238000002360 preparation method Methods 0.000 title claims abstract description 20
- 201000011510 cancer Diseases 0.000 claims abstract description 38
- 230000035755 proliferation Effects 0.000 claims abstract description 29
- 239000006187 pill Substances 0.000 claims abstract description 26
- 206010059866 Drug resistance Diseases 0.000 claims abstract description 21
- 241000717739 Boswellia sacra Species 0.000 claims abstract description 9
- 239000004863 Frankincense Substances 0.000 claims abstract description 9
- 208000016691 refractory malignant neoplasm Diseases 0.000 claims abstract description 8
- 206010027476 Metastases Diseases 0.000 claims abstract description 7
- 230000009401 metastasis Effects 0.000 claims abstract description 7
- 229910052957 realgar Inorganic materials 0.000 claims abstract description 7
- 241001057584 Myrrha Species 0.000 claims abstract description 6
- 239000002994 raw material Substances 0.000 claims abstract description 6
- 206010009944 Colon cancer Diseases 0.000 claims description 11
- 208000029742 colonic neoplasm Diseases 0.000 claims description 11
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 10
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 10
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 10
- 201000010881 cervical cancer Diseases 0.000 claims description 10
- 201000005202 lung cancer Diseases 0.000 claims description 10
- 208000020816 lung neoplasm Diseases 0.000 claims description 10
- 230000002401 inhibitory effect Effects 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 206010060862 Prostate cancer Diseases 0.000 claims description 8
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 8
- 208000032839 leukemia Diseases 0.000 claims description 8
- 201000007270 liver cancer Diseases 0.000 claims description 8
- 208000014018 liver neoplasm Diseases 0.000 claims description 8
- 238000009472 formulation Methods 0.000 claims description 7
- JHGWQSGWUPCKNT-UHFFFAOYSA-N 2-tert-butyl-4-methyl-1,3,5-trinitrobenzene Chemical compound CC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C(C(C)(C)C)=C1[N+]([O-])=O JHGWQSGWUPCKNT-UHFFFAOYSA-N 0.000 claims description 3
- 235000003717 Boswellia sacra Nutrition 0.000 claims description 3
- 235000012035 Boswellia serrata Nutrition 0.000 claims description 3
- 240000007311 Commiphora myrrha Species 0.000 claims description 3
- 235000006965 Commiphora myrrha Nutrition 0.000 claims description 3
- 244000153234 Hibiscus abelmoschus Species 0.000 claims description 3
- 235000007265 Myrrhis odorata Nutrition 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007937 lozenge Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 229940098465 tincture Drugs 0.000 claims description 2
- 238000007796 conventional method Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 210000002966 serum Anatomy 0.000 abstract description 57
- 230000000235 effect on cancer Effects 0.000 abstract description 3
- 238000000338 in vitro Methods 0.000 abstract description 3
- 241000972155 Moschus Species 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 114
- 241000700159 Rattus Species 0.000 description 76
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 24
- 230000005764 inhibitory process Effects 0.000 description 16
- 238000000034 method Methods 0.000 description 13
- 229930182555 Penicillin Natural products 0.000 description 12
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 12
- 238000004113 cell culture Methods 0.000 description 12
- 229940049954 penicillin Drugs 0.000 description 12
- 229960005322 streptomycin Drugs 0.000 description 12
- 239000002609 medium Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 238000011081 inoculation Methods 0.000 description 7
- 239000002054 inoculum Substances 0.000 description 7
- 230000002441 reversible effect Effects 0.000 description 7
- JUJBNYBVVQSIOU-UHFFFAOYSA-M sodium;4-[2-(4-iodophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].C1=CC([N+](=O)[O-])=CC=C1N1[N+](C=2C=CC(I)=CC=2)=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=N1 JUJBNYBVVQSIOU-UHFFFAOYSA-M 0.000 description 7
- 238000012258 culturing Methods 0.000 description 6
- MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 description 5
- 229960002918 doxorubicin hydrochloride Drugs 0.000 description 5
- 230000035876 healing Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 230000003698 anagen phase Effects 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000009702 cancer cell proliferation Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000000306 component Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000005426 pharmaceutical component Substances 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 235000021419 vinegar Nutrition 0.000 description 2
- 239000000052 vinegar Substances 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 101000573199 Homo sapiens Protein PML Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 102000054896 human PML Human genes 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000007971 pharmaceutical suspension Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/36—Arsenic; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/55—Glands not provided for in groups A61K35/22 - A61K35/545, e.g. thyroids, parathyroids or pineal glands
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/324—Boswellia, e.g. frankincense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/328—Commiphora, e.g. mecca myrrh or balm of Gilead
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Inorganic Chemistry (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a pharmaceutical composition and application of a preparation thereof in preparing medicines for treating cancers, wherein the pharmaceutical composition comprises the following raw material medicines: realgar, moschus, olibanum and Myrrha. According to the embodiment of the invention, the rat serum containing the Xingxiao pill medicine components is used for in-vitro culture of cancer cells, so that the cancer cells can be inhibited from proliferation and metastasis, and the drug resistance of drug-resistant cancer cells can be reversed, and therefore, the pharmaceutical composition in the Xingxiao pill formula has a certain treatment effect on cancers. The invention expands the medical application of the Xingxiao pill formula and simultaneously provides a new direction for the treatment of cancers.
Description
Technical Field
The invention relates to the field of pharmaceutical preparations, in particular to a pharmaceutical composition and application of the pharmaceutical composition in preparation of a medicament for treating cancers.
Background
The traditional Chinese medicine has cultural implications for thousands of years, is based on the overall dialectical treatment of traditional Chinese medicine, has the advantage of small adverse reaction, and is often used as an auxiliary drug in the current clinical treatment scheme of cancers. For most cancer advanced patients who are ineffective in radiotherapy and chemotherapy, the selection of traditional Chinese medicine conservative treatment is an important method for improving the life quality and the prognosis of the patients. Therefore, the traditional Chinese medicine has wide application prospect in cancer treatment.
The XINGXIAO pill is prepared from QINGCHONGSHUANG (sic) Wang Hongxu (surgical syndrome treating and total life album), and is prepared from Realgar, moschus, olibanum (preparata), and Myrrha (preparata), and has effects of promoting blood circulation, relieving swelling, and relieving pain, and can be used for treating carbuncle, cellulitis, and swelling and hard pain. There is no report on the clinical treatment of cancer using the Xingxiao pill formula.
Disclosure of Invention
Therefore, the technical problem to be solved by the invention is to provide a pharmaceutical composition in a Xingxiao pill formula and application of a preparation thereof in preparing a medicine for treating cancer.
Therefore, the invention provides a pharmaceutical composition and application of a preparation thereof in preparing medicines for treating cancers, wherein the pharmaceutical composition consists of the following raw materials: realgar, moschus, olibanum and Myrrha. Specifically, the Olibanum can be vinegar processed Olibanum and the Myrrha can be vinegar processed Myrrha.
According to the present invention, the use may vary within a certain range, for example, the use may be the use in the preparation of a medicament for inhibiting proliferation of cancer cells, or the use may be the use in the preparation of a medicament for inhibiting metastasis of cancer cells, or the use may be the use in the preparation of a medicament for reversing drug resistance of drug resistant cancer cells. Specifically, the pharmaceutical composition can treat cancer by inhibiting cancer cell proliferation, inhibiting cancer cell metastasis, or reversing drug resistance of drug resistant cancer cells, and the like.
According to the present invention, the kind of the cancer may vary within a certain range, and for example, the cancer may include at least one of lung cancer, liver cancer, colon cancer, cervical cancer, prostate cancer, or leukemia.
According to the invention, the content of each raw material medicine in the pharmaceutical composition can be changed within a certain range, and in a preferred case, the pharmaceutical composition can be composed of the following raw material medicines in parts by weight: 100 parts of realgar, 30 parts of artificial musk, 200 parts of frankincense and 200 parts of myrrh. In this preferred case, the pharmaceutical composition has a more remarkable therapeutic effect on cancer.
According to the invention, the pharmaceutical composition can be added with conventional auxiliary materials and prepared into clinically acceptable preparations according to a conventional process. The type of the preparation may vary within a certain range, and for example, the preparation may include a tablet, a capsule, a granule, a powder, a syrup, a pill, a tincture, a medicated wine, a soft extract, a lozenge, an injection, or a mixture. Preferably, the formulation is a pill.
According to the present invention, the daily dosage of the pharmaceutical composition may be 3 to 6g.
The technical scheme of the invention has the following advantages:
1. the invention provides a pharmaceutical composition in a Xingxiao pill formula and application of a preparation thereof in preparing a medicament for treating cancer. According to the embodiment of the invention, the rat serum containing the Xingxiao pill medicine components is used for in-vitro culture of cancer cells, so that the cancer cells can be inhibited from proliferation and metastasis, and the drug resistance of drug-resistant cancer cells can be reversed, and therefore, the pharmaceutical composition in the Xingxiao pill formula has a certain treatment effect on cancers. The invention expands the medical application of the Xingxiao pill formula and simultaneously provides a new direction for the treatment of cancers.
2. According to the embodiment of the invention, the rat serum containing the pharmaceutical components of the Xingxiao pill has more obvious proliferation inhibition effect on lung cancer cells (A549, SK-MES-1 and NCI-H69), liver cancer cells (HepG 2), colon cancer cells (HT-29 and HCT-116), cervical cancer cells (Hela and SiHa), prostate cancer cells (PC-3 and DU-145) and leukemia cells (K-562 and HL-60), so that the pharmaceutical composition in the Xingxiao pill formula has better treatment effect on lung cancer, liver cancer, colon cancer, cervical cancer, prostate cancer and leukemia.
Detailed Description
The following examples are provided for a better understanding of the present invention and are not limited to the preferred embodiments described herein, but are not intended to limit the scope of the invention, any product which is the same or similar to the present invention, whether in light of the present teachings or in combination with other prior art features, falls within the scope of the present invention.
The specific experimental procedures or conditions are not noted in the examples and may be followed by the operations or conditions of conventional experimental procedures described in the literature in this field. The reagents or apparatus used were conventional reagent products commercially available without the manufacturer's knowledge.
The cancer cell lines involved in the examples of the present invention were as follows:
lung cancer cell line: a549 (adenocarcinoma), SK-MES-1 (squamous carcinoma), NCI-H69 (small cell lung carcinoma);
colon cancer cell line: HT-29 (hyperdifferentiation), HCT-116 (hypodifferentiation adenocarcinoma),
Liver cancer cell lines: hepG2 (high differentiation)
Cervical cancer cell line: hela, siHa (cervical squamous carcinoma of human)
Prostate cancer cell line: PC-3, DU-145
Leukemia cell line: k-562 (human chronic myelogenous leukemia cells), HL-60 (human promyelocytic leukemia).
Example 1
This example is useful in demonstrating the inhibitory effect of pharmaceutical compositions of the Xingxiao pill formulation on cancer cell proliferation. The pharmaceutical composition involved in this example is: 100 parts of realgar, 30 parts of artificial musk, 200 parts of frankincense (manufactured) and 200 parts of myrrh (manufactured).
(1) Preparation of rat serum (rat drug-containing serum and rat blank serum)
The SPF SD rats are selected from 20, male and female rats, each with weight of 220-240 g, and after adaptive feeding for 3-5 days, the rats are randomly divided into blank control groups and administration groups according to weight, and each group comprises 10 rats. The pharmaceutical composition was ground and mixed well, and then a pharmaceutical suspension containing 0.24g of drug per ml was prepared with distilled water. The daily dose of the rats was determined to be 5ml/kg based on the equivalent dose of the human and the rats converted to the equivalent dose of 2 times the equivalent dose of the rats.
Rats in the administration group were perfused with the drug suspension according to the above dose, rats in the blank group were perfused with an equal amount of distilled water, each rat was administered 2 times daily for 3 days, and after 1 hour of administration in the morning of day 4 (no water forbidden before administration for 12 hours), were anesthetized with sodium pentobarbital, and blood was taken from the abdominal aorta, and the obtained blood was allowed to stand for 2 hours, centrifuged (3000 rpm,10 min), serum was collected, and inactivated at 56 ℃ for 30min, to obtain a rat drug-containing serum and a rat blank serum, which were packaged and stored at-80 ℃ for use.
(2) Determination of the Effect of drug-containing serum on proliferation of Each cancer cell line
Each cancer cell line was routinely cultured according to the culture method. The basal culture broth is a cell culture broth containing 100U/ml penicillin, 100mg/ml streptomycin and 10% fetal bovine serum. The test medium is a cell culture solution containing 100U/ml penicillin, 100mg/ml streptomycin and rat serum, wherein the concentration of the rat serum can be adjusted according to the requirement.
First, basic culture is performed by using basic culture solution, and each cancer cell is cultured at 1×10 5 A concentration of/ml was seeded in 96-well plates at 100. Mu.L per well. After 24 hours of basal culture, each cancer cell was divided into seven groups and subjected to experimental culture using the experimental medium, each group of which was as follows:
normal growth group: cell culture broth containing 100U/ml penicillin, 100mg/ml streptomycin and 10% fetal bovine serum;
10% rat blank serogroup: cell culture broth containing 100U/ml penicillin, 100mg/ml streptomycin and 10% rat blank serum;
20% rat null serogroup: cell culture broth containing 100U/ml penicillin, 100mg/ml streptomycin and 20% rat blank serum;
30% rat blank serogroup: cell culture broth containing 100U/ml penicillin, 100mg/ml streptomycin and 30% rat blank serum;
10% rat drug-containing serogroup: cell culture broth containing 100U/ml penicillin, 100mg/ml streptomycin and 10% rat medicated serum;
20% rat drug-containing serogroup: cell culture broth containing 100U/ml penicillin, 100mg/ml streptomycin and 20% rat medicated serum;
30% rat drug-containing serogroup: cell culture broth containing 100U/ml penicillin, 100mg/ml streptomycin and 30% rat medicated serum.
After 6 compound wells are cultured in each group of cancer cells, normal growth group is cultured for 24 hours, group containing rat blank serum is cultured for 48 hours, group containing rat drug-containing serum is cultured for 72 hours, proliferation inhibition rate (average value of 6 compound wells) of each concentration of rat drug-containing serum on the cancer cells is detected, and detection results are shown in table 1. The method for measuring the proliferation rate of cancer cells may be a method conventional in the art, and may be, for example, an MTT method, an SRB method, or a WST-1 method, and the proliferation inhibition rate of each concentration of rat drug-containing serum on cancer cells is calculated by:
TABLE 1 proliferation inhibition test results of rat serum containing drugs on each cancer cell
Because the sensitivity of various cancer cells to serum content is different, the inhibition rate of proliferation effect of various cancer cells by rat drug-containing serum is not in linear relation with the concentration of the rat drug-containing serum, in particular, the sensitivity of colon cancer HT-29 cells to serum content is stronger, so that the proliferation inhibition rate of 10% concentration of rat drug-containing serum to rat drug-containing serum with concentration higher than 20% and 30% concentration is caused.
As can be seen from Table 1, the pharmaceutical compositions used in this example have remarkable inhibitory effects on the proliferation of lung cancer cells (A549, SK-MES-1, NCI-H69), liver cancer cells (HepG 2), colon cancer cells (HT-29, HCT-116), cervical cancer cells (Hela, siHa), prostate cancer cells (PC-3, DU-145) and leukemia cells (K-562, HL-60) (P < 0.05).
Example 2
This example is useful in demonstrating the inhibition of cancer metastasis by pharmaceutical compositions formulated in XINGXIAO pill formulations. The rat serum used in this example was prepared from example 1.
(1) Scribing lines on the bottom plate of the 6-pore plate, and setting the interval between two adjacent lines to be about 1cm, so that 4-5 lines penetrate through each pore. The cell concentration was set at 5X 10 5 Inoculating cancer cells of each ml into a streaked 6-well plate, wherein the inoculum size of each well is 2.5ml, and culturing overnight after the inoculation is finished, so that the cancer cells are paved on the surface of the culture well;
(2) Making cell scratches on the cell surface by using 200 μl gun head perpendicular to the scribing lines on the surface of the well plate and the bottom plate, discarding the old culture medium, and washing with PBS three times (soft washing, sticking to the wall, adding PBS, slightly shaking, avoiding washing away cells) to remove the scratched cells;
(3) Dividing the culture plates obtained in the step (2) into 3 groups, and adding culture medium into each group according to the following configuration:
a first group: 10% FBS group, adding cell culture solution containing 100U/ml penicillin, 100mg/ml streptomycin and 10% fetal bovine serum;
second group: 30% rat blank serogroup, adding cell culture solution containing 100U/ml penicillin, 100mg/ml streptomycin and 30% rat blank serum;
third group: 30% of rat drug-containing serogroup, adding cell culture solution containing 100U/ml penicillin, 100mg/ml streptomycin and 30% of rat drug-containing serum;
(4) Photographing each group of culture plates obtained in the step (3), placing the culture plates in an incubator for culturing for 24 hours, photographing, and analyzing data by using image pro plus to calculate the corresponding scratch healing rate of each group of culture plates. Scratch healing rate (%) = (scratch area before incubation-scratch area after incubation for 24 h)/scratch area before incubation x 100%.
Repeating the steps (1) to (4) to obtain the scratch healing rate of the cervical cancer SiHa cells, the lung cancer A549 cells and the colon cancer HCT-116 cells under each culture condition, and the results are shown in Table 2.
TABLE 2 detection of scratch healing Rate of cancer cells
As can be seen from table 2, the scratch healing rate of cancer cells in the third group (rat drug-containing serogroup) was significantly reduced compared with the second group (rat blank serogroup), which indicates that the pharmaceutical composition used in this example has an inhibitory effect (P < 0.05) on migration of colon cancer cells HCT-116, cervical cancer cells SiHa, lung cancer cells a 549.
Example 3
This example illustrates the reversal of drug resistance of drug-resistant cancer cells A549/5-FU by drug-resistant pharmaceutical compositions of XINGXIAO pill formulations. The rat serum used in this example was prepared from example 1.
1. Reverse action of Xingxiao pill formula pharmaceutical composition on drug resistance of A549/5-FU cells
(1) Determination of A549/5-FU cell resistance index
Inoculating A549 cells and A549/5-FU cells into 96-well plates in logarithmic phase at a concentration of 5×10 5 The inoculum size was 100. Mu.l/well per ml. After the inoculation was completed, each cell was divided into 8 groups, and each group was cultured with a medium containing 0. Mu.g/ml, 31.25. Mu.g/ml, 62.5. Mu.g/ml, 125. Mu.g/ml, 250. Mu.g/ml, 500. Mu.g/ml, 750. Mu.g/ml and 1000. Mu.g/ml of 5-FU, respectively. After 48 hours of culture, the proliferation of each cell group was measured by the WST-1 method, and the proliferation inhibition ratio of each 5-FU concentration to the two cells was calculated. Calculation of IC of two cells under 5-FU Using SPSS software 50 Values were obtained and the resistance index RI of A549/5-FU cells was calculated.
Drug resistance index ri=ic 50 (A549/5-FU)/IC 50 (A549)。
The drug resistance index of A549/5-FU cells was calculated to be 70.31.
(2) Determination of optimal concentration of drug to reverse resistance
Inoculating A549 cells and A549/5-FU cells into 96-well plates in logarithmic phase at a concentration of 5×10 5 The inoculum size was 100. Mu.l/well per ml. After the inoculation was completed, each cell was divided into 6 groups, and each group was cultured with a medium containing 10%, 20% and 30% rat serum (rat blank serum and rat drug-containing serum), respectively. After culturing for 48 hours, the proliferation condition of each cell group is respectively measured by using a WST-1 method, and the proliferation inhibition rate of the rat drug-containing serum on the two cells is calculated. Selecting the optimal concentration for reversing the drug resistance of the rat drug-containing serum concentration gradient when the proliferation inhibition rate is less than 10 percent, and measuring the drug resistance reversal times of the concentration gradient to the A549/5-FU cells.
The optimal concentration for reversing drug resistance of the rat drug-containing serum is determined to be 10% through calculation.
(3) Determination of fold reverse resistance of drug to A549/5-FU cells
Inoculating A549/5-FU cells in logarithmic phase into 96-well plate at a concentration of 5×10 5 The inoculum size was 100. Mu.l/well per ml. After inoculation, the animals are divided into three groups, wherein the first group is A549/5-FU group, the second group is A549/5-FU+rat blank serogroup, and the third group is A549/5-FU+rat medicated serogroup. Each large group was subdivided into 8 groups and each group was incubated with medium containing 0. Mu.g/ml, 31.25. Mu.g/ml, 62.5. Mu.g/ml, 125. Mu.g/ml, 250. Mu.g/ml, 500. Mu.g/ml, 750. Mu.g/ml and 1000. Mu.g/ml of 5-FU, respectively. After culturing for 48 hours, the proliferation of cells was measured by the WST-1 method, and the proliferation inhibition ratio of each 5-FU concentration to each large group of cells was calculated. Calculation of IC under 5-FU for each Large group of cells Using SPSS software 50 Values were calculated and the inverse fold of resistance to A549/5-FU cells was calculated for the rat serum in the second and third large groups, respectively, and the calculated results are shown in Table 3.
Drug resistance reversal fold = IC 50 (A549/5-FU+ rat serum)/IC 50 (A549/5-FU)。
TABLE 3 determination of fold-reverse resistance of rat medicated serum to A549/5-FU cells
As can be seen from Table 3, the pharmaceutical compositions used in this example had a significant reversal of the resistance to A549/5-FU cells to the rat blank serum ratio (P < 0.001).
Example 4
This example illustrates the reversal of drug resistance of drug-resistant cancer cells HepG2/ADR by a pharmaceutical composition of the Xingxiao pill formulation. The rat serum used in this example was prepared from example 1.
1. Reverse effect of Xingxiao pill formula pharmaceutical composition on drug resistance of HepG2/ADR cells
(1) Determination of the resistance index to HepG2/ADR cells
HepG2 cells and HepG2/ADR cells were inoculated into 96-well plates at a concentration of 5X 10 in the logarithmic growth phase, respectively 5 The inoculum size was 100. Mu.l/well per ml. After the inoculation was completed, each cell was divided into 7 groups, and each group was cultured with a medium containing 0. Mu.g/ml, 5. Mu.g/ml, 10. Mu.g/ml, 15. Mu.g/ml, 20. Mu.g/ml, 25. Mu.g/ml, 30. Mu.g/ml doxorubicin hydrochloride, respectively. After 48h of culture, the proliferation of each cell group was measured by the WST-1 method, and the proliferation inhibition ratio of each doxorubicin hydrochloride concentration to the two cells was calculated. Calculation of IC of two cells under the action of doxorubicin hydrochloride Using SPSS software 50 Values were calculated and the resistance index RI of HepG2/ADR cells was calculated.
Drug resistance index ri=ic 50 (HepG2)/IC 50 (HepG2/ADR)。
The resistance index of HepG2/ADR cells was calculated to be 1.175.
(2) Determination of optimal concentration of drug to reverse resistance
HepG2 cells and HepG2/ADR cells were inoculated into 96-well plates at a concentration of 5X 10 in the logarithmic growth phase, respectively 5 The inoculum size was 100. Mu.l/well per ml. After the inoculation was completed, each cell was divided into 6 groups, and each group was cultured with a medium containing 10%, 20% and 30% rat serum (rat blank serum and rat drug-containing serum), respectively.After culturing for 48 hours, the proliferation condition of each cell group is respectively measured by using a WST-1 method, and the proliferation inhibition rate of the rat drug-containing serum on the two cells is calculated. The concentration gradient of the rat drug-containing serum with the proliferation inhibition rate less than 10% is selected as the optimal concentration for reversing the drug resistance, and the drug resistance reversal multiple of the concentration gradient to HepG2/ADR cells is measured.
The optimal concentration for reversing drug resistance of the rat drug-containing serum is determined to be 10% through calculation.
(3) Determination of fold reverse resistance of drug to HepG2/ADR cells
HepG2/ADR cells were seeded in 96-well plates at a concentration of 5X 10 in the logarithmic growth phase 5 The inoculum size was 100. Mu.l/well per ml. After inoculation, the animals were divided into three groups, the first group was HepG2/ADR, the second group was HepG 2/ADR+rat blank serogroup, and the third group was HepG 2/ADR+rat drug-containing serogroup. Each large group was subdivided into 7 groups and each group was incubated with medium containing 0. Mu.g/ml, 5. Mu.g/ml, 10. Mu.g/ml, 15. Mu.g/ml, 20. Mu.g/ml, 25. Mu.g/ml, 30. Mu.g/ml doxorubicin hydrochloride. After culturing for 48 hours, the proliferation conditions of the cells are respectively measured by using a WST-1 method, and the proliferation inhibition rate of each doxorubicin hydrochloride concentration on each large group of cells is calculated. Calculation of IC under Dorubicin hydrochloride for each Large group of cells Using SPSS software 50 Values were calculated and the inverse fold of resistance to HepG2/ADR cells was calculated for the rat serum in the second and third groups, respectively, and the calculated results are shown in table 4.
Drug resistance reversal fold = IC 50 (HepG2/ADR)/IC 50 (HepG 2/ADR+ rat serum).
TABLE 4 determination of fold-reverse resistance of rat medicated serum to HepG2/ADR cells
As can be seen from Table 4, the pharmaceutical compositions used in this example had a significant reversal of resistance to HepG2/ADR cells compared to the rat blank serum (P < 0.01).
Therefore, the embodiment of the invention utilizes rat serum containing the components of the Xingxiao pill to culture cancer cells in vitro, and discovers that the rat serum can inhibit proliferation and metastasis of cancer cells and can reverse drug resistance of drug-resistant cancer cells, so that the pharmaceutical composition in the Xingxiao pill formula has a certain treatment effect on cancers. Furthermore, the rat serum containing the pharmaceutical components of the Xingxiao pill has more obvious proliferation inhibition effect on lung cancer cells (A549, SK-MES-1 and NCI-H69), liver cancer cells (HepG 2), colon cancer cells (HT-29 and HCT-116), cervical cancer cells (Hela and SiHa), prostate cancer cells (PC-3 and DU-145) and leukemia cells (K-562 and HL-60), so that the pharmaceutical composition in the Xingxiao pill formula has better treatment effect on lung cancer, liver cancer, colon cancer, cervical cancer, prostate cancer and leukemia.
It is apparent that the above examples are given by way of illustration only and are not limiting of the embodiments. Other variations or modifications of the above teachings will be apparent to those of ordinary skill in the art. It is not necessary here nor is it exhaustive of all embodiments. While still being apparent from variations or modifications that may be made by those skilled in the art are within the scope of the invention.
Claims (9)
1. The application of the pharmaceutical composition and the preparation thereof in preparing medicines for treating cancers is provided, wherein the pharmaceutical composition consists of the following raw materials: realgar, moschus, olibanum and Myrrha.
2. The use according to claim 1, characterized in that it is in the preparation of a medicament for inhibiting proliferation of cancer cells.
3. The use according to claim 1, characterized in that it is in the preparation of a medicament for inhibiting metastasis of cancer cells.
4. The use according to claim 1, wherein the use is in the manufacture of a medicament for reversing drug resistance of drug resistant cancer cells.
5. The use according to any one of claims 1 to 4, wherein the cancer comprises at least one of lung cancer, liver cancer, colon cancer, cervical cancer, prostate cancer or leukemia.
6. The use according to any one of claims 1 to 4, wherein the pharmaceutical composition consists of the following raw materials in parts by weight:
100 parts of realgar, 30 parts of artificial musk, 200 parts of frankincense and 200 parts of myrrh.
7. The use according to any one of claims 1 to 4, wherein the pharmaceutical composition is formulated into a clinically acceptable formulation by adding conventional excipients according to conventional techniques.
8. The use according to claim 7, wherein the preparation comprises a tablet, capsule, granule, powder, syrup, pill, tincture, medicated wine, decoction, lozenge, injection or mixture;
preferably, the formulation is a pill.
9. The use according to any one of claims 1 to 4, wherein the pharmaceutical composition is administered in a daily dose of 3 to 6g.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111626099.2A CN116407576A (en) | 2021-12-29 | 2021-12-29 | Pharmaceutical composition and application of preparation thereof in preparation of medicines for treating cancers |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111626099.2A CN116407576A (en) | 2021-12-29 | 2021-12-29 | Pharmaceutical composition and application of preparation thereof in preparation of medicines for treating cancers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116407576A true CN116407576A (en) | 2023-07-11 |
Family
ID=87053033
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111626099.2A Pending CN116407576A (en) | 2021-12-29 | 2021-12-29 | Pharmaceutical composition and application of preparation thereof in preparation of medicines for treating cancers |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116407576A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1965888A (en) * | 2005-11-19 | 2007-05-23 | 刘立惠 | Chinese medicinal composition for treating breast cancer |
-
2021
- 2021-12-29 CN CN202111626099.2A patent/CN116407576A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1965888A (en) * | 2005-11-19 | 2007-05-23 | 刘立惠 | Chinese medicinal composition for treating breast cancer |
Non-Patent Citations (5)
| Title |
|---|
| 周相男: "醒消丸治疗恶性肿瘤的临床应用探讨", 广州中医药大学学报, vol. 38, no. 8, 31 August 2021 (2021-08-31), pages 1745 - 1749 * |
| 周相男等: "基于网络药理学和分子对接分析醒消丸治疗肺癌潜在靶点及作用机制", 海南医学院学报, vol. 10, 19 May 2021 (2021-05-19), pages 1 - 14 * |
| 张培钦等: "《消化道疾病》", vol. 1, 31 May 2003, 广州出版社, pages: 376 * |
| 李佩文等: "《癌症疼痛中西医汇通》", vol. 1, 31 January 2002, 辽宁科学技术出版社, pages: 196 * |
| 李彪等: "《现代中西医结合.实用外科手册》", vol. 1, 31 January 1999, 湖南科学技术出版社, pages: 472 - 473 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20210085630A1 (en) | Pharmaceutical composition and use thereof in preparing drug for treating tumor multi-drug resistance | |
| US11033519B2 (en) | Drug combination with antitumor effects | |
| US20230310394A1 (en) | Sorafenib, regorafenib and novel use of analogue or derivative thereof | |
| WO2017162055A1 (en) | Application of cyclic dinucleotide cgamp-liposome for resisting tumours | |
| CN114948938B (en) | Application of atractylenolide I in preparation of medicine for preventing and/or treating cervical cancer | |
| TWI831999B (en) | Chidamide pharmaceutical composition and application thereof | |
| CN111346081A (en) | New use of pharmaceutical composition comprising n-pentanoic acid, indolpropanic acid and sodium n-butyrate | |
| CN113925867A (en) | Application of dronedarone hydrochloride and 5-fluorouracil in preparation of antitumor drugs | |
| CN116407576A (en) | Pharmaceutical composition and application of preparation thereof in preparation of medicines for treating cancers | |
| CN109453183B (en) | Tumor multidrug resistance reversal agent or anti-tumor medicine sensitizer of melissoside and application thereof | |
| CN101032478A (en) | Application of triptolide in the preparing of anti-alimentary tract tumor medicine | |
| CN108295085B (en) | Application of protodioscin in preparation of drug-resistant osteosarcoma drug | |
| WO2018058863A1 (en) | Use of polyether compounds | |
| CN112535689B (en) | Application of liquidambar formosana lactone in treating cancers | |
| CN103417620B (en) | Application of serrate rabdosia herb extract serving as STAT3 signal specific inhibiter in preparation of anti-tumor drug | |
| CN113440519A (en) | Application of mycophenolic acid and derivatives thereof in preparation of drugs for targeted therapy of cancers | |
| US10688086B2 (en) | Method for treating cancer with dihydropyridine calcium antagonist | |
| CN116549478B (en) | Pharmaceutical composition and preparation method and application thereof | |
| US11617729B2 (en) | Uses of guanidine hydrochloride as a drug for treating cancers/tumors | |
| WO2023011415A1 (en) | Pharmaceutical composition of egfr inhibitor and use thereof | |
| CN115286574B (en) | BLVRB enzyme function inhibitor and preparation method and application thereof | |
| US11547715B2 (en) | Use of chlorogenic acid in preparation of drug for treating chordoma | |
| US20220339175A1 (en) | Application of Stachyose in Preparation of Drug for Treating Castration-Resistant Prostate Cancer | |
| CN116808052A (en) | Application of D-mannose in preparation of EGFR protein degradation drugs | |
| CN113876780A (en) | Pharmaceutical composition and application thereof in preparation of medicines for treating non-small cell lung cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |